Unichem Laboratories Approves Unaudited Financial Results for Q2 & H1 Ended Sep 25
Unichem Laboratories' board approves Q2 and H1 FY26 unaudited financial results on November 11, 2025, showcasing consolidated revenue of ₹578.96 crore for the quarter and ₹1,105.56 crore for the half-year.
The financial results show a mixed performance, with revenue increases in some areas but losses before and after tax, suggesting a potentially medium impact on the company's stock.
The announcement primarily contains financial results, which are presented without positive or negative language. Therefore, the sentiment is neutral.
* Unichem Laboratories Limited's Board of Directors approved the Unaudited Financial Statements (Consolidated & Standalone) for the second quarter and half year ended 30th September 2025 on 11th November 2025. * The board meeting commenced at 11:00 a.m. and concluded at 01:00 p.m. * Consolidated Financial Results for the Quarter ended 30th September 2025: * Revenue from operations: ₹578.96 crore compared to ₹507.36 crore in the corresponding quarter last year. * Total Income: ₹599.93 crore. * Profit/ (Loss) before tax: ₹(10.82) crore. * Profit/ (Loss) for the period after tax: ₹(11.89) crore. * Consolidated Financial Results for the Half year ended 30th September 2025: * Revenue from operations ₹1,105.56 crore (₹990.70 crore previous year) * Total Income ₹1,133.35 crore. * Profit/ (Loss) before tax ₹(19.84) crore. * Profit/ (Loss) for the period after tax ₹(22.36) crore. * Standalone Financial Results for the Quarter ended 30th September 2025: * Revenue from operations: ₹356.90 crore compared to ₹436.88 crore in the corresponding quarter last year. * Total Income: ₹378.30 crore. * Profit / (Loss) before tax: ₹(37.83) crore. * Profit / (Loss) for the period after tax: ₹(39.93) crore. * Standalone Financial Results for the Half year ended 30th September 2025: * Revenue from operations ₹741.15 crore (₹826.63 crore previous year). * Total Income ₹766.80 crore. * Profit / (Loss) before tax ₹(39.70) crore. * Profit / (Loss) for the period after tax ₹(41.78) crore.
What to do with a filing like this
Unichem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Unichem Laboratories Limited. Read the original for the full detail.